Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal Function, and Angiotensin Receptor Blockers
نویسندگان
چکیده
منابع مشابه
Angiotensin II subtype 1 receptor blockers and renal function.
Blood pressure reduction is the most significant factor in delaying onset and progression of renal disease. Blockade of the renin-angiotensin system (RAS) using angiotensin-converting enzyme inhibitors (ACEIs) delays renal disease progression. More recently, agents that block the RAS by preventing angiotensin II from binding to its subtype 1 receptor (ARBs) have been developed in an effort to p...
متن کاملAspirin and platelet function
1 Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655–62. 2 JyW,MaoWW,Horstman LL, Tao J, AhnYS. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Molecules Dis 1995; 21: 217–31. 3 Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin M...
متن کاملAngiotensin II receptor blockers.
BUMC PROCEEDINGS 2003;16:123–126 The angiotensin II receptor blockers (ARBs) represent a newer class of antihypertensive agents. Their mechanism of action differs from that of the angiotensin-converting enzyme (ACE) inhibitors, which also affect the renin-angiotensin system. The ARBs were developed to overcome several of the deficiencies of ACE inhibitors: competitive inhibition of ACE results ...
متن کاملAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established.Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the...
متن کاملAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
Reducing the actions of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) slows nephropathy progression in patients with or without diabetes. These drug classes have proven therapeutic benefits, particularly in patients with renal insufficiency (ie, serum creatinine level 133-265 micromol/L [1.5-3.0 m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Applied Thrombosis/Hemostasis
سال: 2018
ISSN: 1076-0296,1938-2723
DOI: 10.1177/1076029618786588